Division of Hematology/Oncology, Department of Medicine and UI Cancer Center, University of Illinois at Chicago, Chicago, IL, United States.
Front Immunol. 2019 Jan 22;9:3186. doi: 10.3389/fimmu.2018.03186. eCollection 2018.
Early release of TNFα after hematopoietic stem cell transplantation (HSCT) correlates with development of acute graft-vs.-host disease (GVHD). Here we tested the effect of TNFα and alloreactive T cells on early hematopoietic HSC genotype and function. Addition of TNFα (10 ng/ml) in liquid cultures with CD34+ cells for 6-72 h resulted in the downregulation of genes associated with stem cell activity, such as DNMT3A, DNMT3B, TET1, TET2, SOX2, NANOG, and OCT4, whereas no significant effect was observed on DNMT1 and GATA2 expression. These findings were reversed by using an anti-TNFα antibody. Similar gene downregulation was observed when CD34+ cells were co-cultured with alloreactive T cells CD34+ cells for 48-72 h, and this effect was partially prevented by rapamycin and an anti-TNFα antibody. CD34+ cells pre-incubated with TNFα for 48 h and transplanted in irradiated NOD-SCID ɤ (NSG) mice showed a reduced myeloid engraftment compared to control mice. By using a xenograft model recently developed in our lab, we co-transplanted CD34+ cells and allogeneic T lymphocytes at 1:0.1 ratio in one group that also received etanercept (TNFα inhibitor) at 100 μg intra-peritoneum (i.p.) on days -1,+1,+3,+5 post-HSCT, and in the control group. At 6 weeks post-transplant, mice that received etanercept had a significantly higher number of marrow huCD45+CD34+CD38- early stem cells ( = 0.03) and a reduced number of huCD45+CD3+ splenic T cells ( = 0.04) compared to controls. The repopulating activity of marrow cells from mice treated with etanercept vs. controls was tested in secondary transplants. Although the overall engraftment was similar in the two groups, CD34+ cells isolated from recipients of marrow from the etanercept group showed a significantly greater expression of stem cell-associated genes and a higher number of CD45+CD34+CD38- cells than in controls ( = 0.03). Our findings suggest that early TNFα increase post-transplant can affect long-term stem cell engraftment, and that blockade of TNFα early after transplant may limit a cytokine-mediated suppressive effect on repopulating stem cell function.
造血干细胞移植(HSCT)后 TNFα 的早期释放与急性移植物抗宿主病(GVHD)的发展有关。在这里,我们测试了 TNFα 和同种反应性 T 细胞对早期造血干细胞基因型和功能的影响。在含有 CD34+细胞的液体培养物中添加 TNFα(10ng/ml)6-72 小时,导致与干细胞活性相关的基因下调,例如 DNMT3A、DNMT3B、TET1、TET2、SOX2、NANOG 和 OCT4,而对 DNMT1 和 GATA2 的表达没有明显影响。使用抗 TNFα 抗体可逆转这些发现。当 CD34+细胞与同种反应性 T 细胞共培养 48-72 小时时,观察到类似的基因下调,而雷帕霉素和抗 TNFα 抗体部分阻止了这种效应。与对照小鼠相比,预先用 TNFα 孵育 48 小时并移植到照射的 NOD-SCID γ(NSG)小鼠中的 CD34+细胞显示出较低的髓系植入。使用我们实验室最近开发的异种移植模型,我们在一组中以 1:0.1 的比例共移植 CD34+细胞和同种异体 T 淋巴细胞,该组在 HSCT 后第-1、+1、+3、+5 天还接受依那西普(TNFα 抑制剂)100μg 腹腔内(i.p.),在对照组中不接受依那西普。在移植后 6 周时,与对照组相比,接受依那西普治疗的小鼠的骨髓 huCD45+CD34+CD38-早期干细胞数量明显增加(=0.03),脾 huCD45+CD3+T 细胞数量减少(=0.04)。依那西普治疗组与对照组之间骨髓细胞的重植活性在二次移植中进行了测试。尽管两组的总体植入情况相似,但与对照组相比,来自依那西普组骨髓的受体分离出的 CD34+细胞表现出与干细胞相关的基因表达显著增加,并且 CD45+CD34+CD38-细胞数量更多(=0.03)。我们的发现表明,移植后早期 TNFα 的增加可能会影响长期的干细胞植入,并且移植后早期阻断 TNFα 可能会限制细胞因子对重植干细胞功能的抑制作用。